Mohammad Mahboob
Pulmonary Disease · Toledo, OHNPI 1164429924
Payments from drug & device makers
Across 293 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$904
- GSK$817
- Boehringer Ingelheim$515
- Jazz Pharmaceuticals Inc.$499
- Grifols USA, LLC$275
- Mylan Specialty L.p.$243
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,224100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $904 |
| GSK | 54 | $817 |
| Boehringer Ingelheim | 23 | $515 |
| Jazz Pharmaceuticals Inc. | 35 | $499 |
| Grifols USA, LLC | 12 | $275 |
| Mylan Specialty L.p. | 15 | $243 |
| Axsome Therapeutics, Inc. | 21 | $211 |
| United Therapeutics Corporation | 14 | $194 |
| Sunovion Pharmaceuticals Inc. | 14 | $188 |
| Genentech USA, Inc. | 4 | $182 |
| Amgen | 5 | $179 |
| Baxter Healthcare | 5 | $156 |
| Harmony Biosciences LLC | 8 | $151 |
| Sanofi | 6 | $123 |
| Electromed, Inc. | 8 | $101 |
| Insmed, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $54 |
| Inogen, Inc. | 4 | $45 |
| Astellas Pharma US Inc | 3 | $43 |
| Advanced Respiratory, Inc | 2 | $37 |
| Eisai Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Circassia Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,236 in reported general payments places this provider in the 65th percentile of 571 pulmonary disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $31,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $26,938 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $7,323 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,124 |
| Montelukast Sodium | 17 | $351 |
| Lamotrigine | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $904 | $38,33850 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $817 | $34,05149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Toledo
- James TitaToledo$310K
- Salil AvasthiToledo$220K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.